{"id":43594,"date":"2025-10-16T16:42:38","date_gmt":"2025-10-16T08:42:38","guid":{"rendered":"https:\/\/flcube.com\/?p=43594"},"modified":"2025-10-16T16:42:39","modified_gmt":"2025-10-16T08:42:39","slug":"jacobio-pharmaceuticals-secures-80-equity-investment-in-jacoray-from-oceanpine-capital","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43594","title":{"rendered":"Jacobio Pharmaceuticals Secures 80% Equity Investment in Jacoray from Oceanpine Capital"},"content":{"rendered":"\n

Jacobio Pharmaceuticals (HKG: 1167<\/a>) today announced a capital\u2011increase and equity\u2011transfer agreement that will see Shanxi Oceanpine Management Consulting Partnership (Limited Partnership)<\/strong> acquire an 80\u202f% stake<\/strong> in Beijing Jacoray Pharmaceutical Technology Co., Ltd.<\/strong> (Jacoray). The deal is part of Jacobio\u2019s strategy to concentrate resources on its core oncology pipeline, including its Pan\u2011KRAS inhibitors and iADC platform.<\/p>\n\n\n\n

Transaction Highlights<\/h3>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Acquiring Party<\/strong><\/td>Oceanpine Capital<\/td><\/tr>
Target Company<\/strong><\/td>Jacoray \u2013 a subsidiary of Beijing Jacobio<\/td><\/tr>
Equity Split Post\u2011Transaction<\/strong><\/td>Beijing Jacobio\u202f10\u202f%, Oceanpine Capital\u202f80\u202f%, Industrial Cooperation Partner\u202f10\u202f%<\/td><\/tr>
Initial Payment<\/strong><\/td>RMB\u202f125\u202fmillion<\/td><\/tr>
Milestone Payments<\/strong><\/td>RMB\u202f75\u202fmillion (subject to performance milestones)<\/td><\/tr>
Use of Proceeds<\/strong><\/td>Research, development, manufacturing and commercialization of Pan\u2011KRAS inhibitors and other oncology assets<\/td><\/tr>
Strategic Rationale<\/strong><\/td>Frees up capital for Jacobio\u2019s oncology focus; aligns with early\u2011stage cardiovascular work at Jincoricon<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context<\/h3>\n\n\n\n